Walgreens Boots Alliance Considers Breakup into Three Separate Companies

TL/DR –

Walgreens Boots Alliance may divide into three separate businesses, diverging from the industry trend of healthcare consolidation. The proposed breakup would see Boots UK and its over 1,800 stores sold or spun off, while Walgreens’ retail pharmacies in the US and its specialty pharmacy business would each become standalone companies. This move comes amid a challenging period for Walgreens, which has struggled to integrate healthcare services into its retail pharmacies, and recently reported a net loss of $265 million for its fiscal first quarter.

Walgreens Boots Alliance Potential Breakup into Three Separate Entities

Potential plans of a breakup of Walgreens Boots Alliance into three entities go against the healthcare industry’s consolidation trend. It’s suggested that the breakup would involve offloading Boots UK, separating Walgreens retail pharmacies in the US, and forming a third company for the fast-growing specialty pharmacy business.

Industry Impact of Potential Walgreens Breakup

This move comes when competitors like CVS Health are consolidating their businesses. CVS Health, for instance, owns Aetna, the nation’s third-largest health insurance company, and Caremark, one of the largest pharmacy benefit management companies. This allows CVS to provide health plan enrollees, employer, and government clients services at discounted prices.

Walgreens’s Struggles with Healthcare Integration

Walgreens has faced challenges in integrating healthcare services into its retail pharmacies. For instance, Walgreens invested over $6 billion in VillageMD to take a controlling stake, aiming to open up to 700 physician-led primary care clinics in more than 30 US markets over five years. However, the ambitious plan has been thwarted due to difficulties in filling patient panels, forcing the company to scale back on clinic expansion.

Walgreens’s Financial Performance and Strategies

Walgreens reported a net loss of $265 million for the fiscal first quarter ended Nov. 30 last year, compared to a $67 million loss the previous year. Meanwhile, the company has been actively seeking to reduce debt by selling off some healthcare assets, such as its stake in VillageMD. Walgreens’ stake in Cencora has also dropped to 6% from 10%, allowing the company to sell shares of the drug distributor for proceeds of about $300 million.

Despite the challenges, Walgreens CEO Tim Wentworth remains optimistic, stating that the company’s first quarter results reflect its disciplined execution against its 2025 priorities: stabilizing the retail pharmacy, controlling operating costs, improving cash flow, and continuing to address reimbursement models.

—
Read More Health & Wellness News ; US News